drugset / Trial / NCT03552276
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
Non-randomizedSequentialOpen-labelTreatment
Summary
A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab
Timeline
- Start
- 2018-07-11
- Primary completion
- 2023-09-18
- Completion
- 2023-09-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tildrakizumab | Monoclonal antibody | 100 mg | — |
| Subject | Tildrakizumab | Monoclonal antibody | 200 mg | — |